Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials

Otsuka

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: Aripiprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00239356

CN138-112

Details and patient eligibility

About

The purpose of this study is to provide aripiprazole to schizophrenic outpatients and Community Treated Patients who are currently receiving aripiprazole therapy on another BMS sponsored clinical trial.

Enrollment: 119 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently receiving aripiprazole at time of screening
• Men and women ages 18 to 70

Exclusion criteria

• All patients previously discontinued from an aripiprazole study for any reason
• Active alcohol or substance abuse
• Patients who represent a significant risk of committing suicide
• Patients with clinically significant abnormal laboratory test results, vital signs or ECG findings

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

119 participants in 1 patient group

AI

Experimental group

Treatment:

Drug: Aripiprazole